On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee worked through seven peptides, deciding whether to recommend each for the 503A list that licensed pharmacies may compound. Here is how the slate landed — and the caveat that applies to every line.

Recommended (6 of 7)

  • BPC-157 — recommended 8–6, tied to a proposed ulcerative-colitis use rather than general wellness.
  • TB-500 (thymosin beta-4 fragment) — recommended.
  • KPV — recommended.
  • MOTS-c — recommended.
  • Semax — recommended.
  • Epitalon — recommended.

Not recommended (1 of 7)

DSIP (delta sleep-inducing peptide, also called emideltide) was the only one the committee declined to recommend.

Still waiting

A separate group of five — GHK-Cu, Melanotan II, Cathelicidin LL-37, Dihexa, and PEG-MGF — was routed to a later consultation expected by early 2027, so they were not voted on in July.

Six “yes” votes make a strong headline. They do not make a legal product — not yet.

The caveat on all of it

Every one of these votes is a recommendation, not a decision. The committee even sided against the FDA’s own scientists, who had argued the evidence supported none of the seven. The FDA must still run formal rulemaking before anything is compoundable, and it has signaled it may not adopt every recommendation. Today, none of these peptides is FDA-approved.